Abstract

BackgroundBladder cancer is one of the most prevalent malignancies worldwide. However, traditional indicators have limited predictive effects on the clinical outcomes of bladder cancer. The aim of this study was to develop and validate a glycolysis-related gene signature for predicting the prognosis of patients with bladder cancer that have limited therapeutic options.MethodsmRNA expression profiling was obtained from patients with bladder cancer from The Cancer Genome Atlas (TCGA) database. Gene set enrichment analysis (GSEA) was conducted to identify glycolytic gene sets that were significantly different between bladder cancer tissues and paired normal tissues. A prognosis-related gene signature was constructed by univariate and multivariate Cox analysis. Kaplan–Meier curves and time-dependent receiver operating characteristic (ROC) curves were utilized to evaluate the signature. A nomogram combined with the gene signature and clinical parameters was constructed. Correlations between glycolysis-related gene signature and molecular characterization as well as cancer subtypes were analyzed. RT-qPCR was applied to analyze gene expression. Functional experiments were performed to determine the role of PKM2 in the proliferation of bladder cancer cells.ResultsUsing a Cox proportional regression model, we established that a 4-mRNA signature (NUP205, NUPL2, PFKFB1 and PKM) was significantly associated with prognosis in bladder cancer patients. Based on the signature, patients were split into high and low risk groups, with different prognostic outcomes. The gene signature was an independent prognostic indicator for overall survival. The ability of the 4-mRNA signature to make an accurate prognosis was tested in two other validation datasets. GSEA was performed to explore the 4-mRNA related canonical pathways and biological processes, such as the cell cycle, hypoxia, p53 pathway, and PI3K/AKT/mTOR pathway. A heatmap showing the correlation between risk score and cell cycle signature was generated. RT-qPCR revealed the genes that were differentially expressed between normal and cancer tissues. Experiments showed that PKM2 plays essential roles in cell proliferation and the cell cycle.ConclusionThe established 4‑mRNA signature may act as a promising model for generating accurate prognoses for patients with bladder cancer, but the specific biological mechanism needs further verification.

Highlights

  • IntroductionTraditional indicators have limited predictive effects on the clinical outcomes of bladder cancer

  • Bladder cancer is one of the most prevalent malignancies worldwide

  • To investigate the relationship between the expression of glycolysis-related genes and the classification of bladder cancer as well as the molecular mechanisms and biological processes involved in cancer development, we explored the distributions of risk score in the following molecular subtypes of bladder cancer from The Cancer Genome Atlas (TCGA) cohort: p53-like signature, TP53 mutation, carcinoma-in situ (CIS) signature, epithelial-mesenchymal transition (EMT) signature, and cell cycle signature

Read more

Summary

Introduction

Traditional indicators have limited predictive effects on the clinical outcomes of bladder cancer. The aim of this study was to develop and validate a glycolysis-related gene signature for predicting the prognosis of patients with bladder cancer that have limited therapeutic options. Bladder cancer is a heterogeneous disease with two major. Over 70% of bladder cancer patients are diagnosed with NMIBC, which has a high rate of recurrence but a low mortality [2]. MIBC is the cause of the majority of deaths from bladder cancer, and it has unsatisfactory long-term survival and a high risk of distant metastasis [3]. It is of vital importance to identify reliable prognostic biomarkers that can predict clinical outcomes and inform decisions about observation, diagnosis, surgery, pharmacological intervention and conservative treatments

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call